⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for gprc5d

Every month we try and update this database with for gprc5d cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNCT06429150
Multiple Myelom...
Plasmacytoma
CAR-T cells
18 Years - 80 YearsShenzhen Geno-Immune Medical Institute
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMNCT05739188
Multiple Myelom...
Multiple Myelom...
Anti-GPRC5D CAR...
18 Years - 75 Years920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple MyelomaNCT06106945
Multiple Myelom...
AZD0305
18 Years - AstraZeneca
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple MyelomaNCT05016778
Multiple Myelom...
GPRC5D-CAR-T
18 Years - 75 YearsZhejiang University
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaNCT06121843
Multiple Myelom...
BMS-986393
Alnuctamab
Mezigdomide
Iberdomide
18 Years - Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNCT06429150
Multiple Myelom...
Plasmacytoma
CAR-T cells
18 Years - 80 YearsShenzhen Geno-Immune Medical Institute
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaNCT06121843
Multiple Myelom...
BMS-986393
Alnuctamab
Mezigdomide
Iberdomide
18 Years - Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCLNCT06333509
Multiple Myelom...
Primary Plasma ...
CT071
18 Years - CARsgen Therapeutics Co., Ltd.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: